Перспективы тераностики глиобластомы с помощью моноклональных антител к рецептору эпидермального фактора роста EGFR

Копылов А.М.

Химический факультет Московского государственного университета им. М.В. Ломоносова

Завьялова Е.Г.

ФГБОУ «Московский государственный университет им. М.В. Ломоносова», Москва, Россия; ООО «Апто-Фарм», Москва, Россия

Павлова Г.В.

ФГБУ "Институт биологии гена" РАН

Пронин И.Н.

НИИ нейрохирургии им. акад. Н.Н. Бурденко РАМН, Москва

Перспективы тераностики глиобластомы с помощью моноклональных антител к рецептору эпидермального фактора роста EGFR

Журнал: Журнал «Вопросы нейрохирургии» имени Н.Н. Бурденко. 2020;84(3): 113-118

DOI 10.17116/neiro202084031113

Загрузок :

Связаться с автором

Как цитировать

Копылов А. М., Завьялова Е. Г., Павлова Г. В., Пронин И. Н. Перспективы тераностики глиобластомы с помощью моноклональных антител к рецептору эпидермального фактора роста EGFR. Журнал «Вопросы нейрохирургии» имени Н.Н. Бурденко. 2020;84(3):113-118. https://doi.org/10.17116/neiro202084031113

Авторы:

Копылов А.М.

Химический факультет Московского государственного университета им. М.В. Ломоносова

Все авторы (4)

Закрыть метаданные

В кратком обзоре литературы проанализированы перспективы тераностики мультиформной глиобластомы (ГБ) с помощью моноклональных антител к рецептору эпидермального фактора роста (EGFR). Несмотря на высокий потенциал использования EGFR, демонстрируемый при лечении злокачественных опухолей различного происхождения, в случае ГБ эффективность тераностики с помощью моноклональных антител к EGFR сдерживается отсутствием информативных критериев оценки эффективности диагностики и лечения заболевания.

Ключевые слова:

тераностика

мультиформная глиобластома

моноклональные антитела

рецептор эпидермального фактора роста EGFR

Авторы:

Копылов А.М.

Химический факультет Московского государственного университета им. М.В. Ломоносова

Завьялова Е.Г.

Павлова Г.В.

ФГБУ "Институт биологии гена" РАН

Пронин И.Н.

НИИ нейрохирургии им. акад. Н.Н. Бурденко РАМН, Москва

Список литературы:

Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, DePinho RA, Cavenee WK. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes and Development. 2007;21(21):2683-2710.
Tan DC, Roth IM, Wickremesekera AC, Davis PF, Kaye AH, Mantamadiotis T, Stylli SS, Tan ST. Therapeutic Targeting of Cancer Stem Cells in Human Glioblastoma by Manipulating the Renin-Angiotensin System. Cells. 2019;8(11):1364. https://doi.org/10.3390/cells8111364
The 2016 World Health Organization Histological Classification of Tumours of the Central Nervous System. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., eds. International Agency for Research on Cancer, France; 2016.
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathologica. 2016;131(6):803-820. https://doi.org/10.1007/s00401-016-1545-1
Stichel D, Ebrahimi A, Reuss D, Schrimpf D, Ono T, Shirahata M, Reifenberger G, Weller M, Hänggi D, Wick W, Herold-Mende C, Westphal M, Brandner S, Pfister SM, Capper D, Sahm F, von Deimling A. Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. Acta Neuropathologica. 2018;136(5):793-803. https://doi.org/10.1007/s00401-018-1905-0
Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu CJ, Genovese G, Shmulevich I, Barnholtz-Sloan J, Zou L, Vegesna R, Shukla SA, Ciriello G, Yung WK, Zhang W, Sougnez C, Mikkelsen T, Aldape K, Bigner DD, Van Meir EG, Prados M, Sloan A, Black KL, Eschbacher J, Finocchiaro G, Friedman W, Andrews DW, Guha A, Iacocca M, O’Neill BP, Foltz G, Myers J, Weisenberger DJ, Penny R, Kucherlapati R, Perou CM, Hayes DN, Gibbs R, Marra M, Mills GB, Lander E, Spellman P, Wilson R, Sander C, Weinstein J, Meyerson M, Gabriel S, Laird PW, Haussler D, Getz G, Chin L. TCGA Research Network. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462-477. Erratum in: Cell. 2014;24;157(3):753. https://doi.org/10.1016/j.cell.2013.09.034
Ymer SI, Greenall SA, Cvrljevic A, Cao DX, Donoghue JF, Epa VC, Scott AM, Adams TE, Johns TG. Glioma specific extracellular missense mutations in the first cysteine rich region of epidermal growth factor receptor (EGFR) initiate ligand independent activation. Cancers (Basel). 2011;3(2):2032-2049. https://doi.org/10.3390/cancers3022032
Reardon DA, Wen PY, Mellinghoff IK. Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges. Neuro-Oncology. 2014;16(8):7-13. https://doi.org/10.1093/neuonc/nou232
Hegi ME, Diserens AC, Bady P, Kamoshima Y, Kouwenhoven MC, Delorenzi M, Lambiv WL, Hamou MF, Matter MS, Koch A, Heppner FL, Yonekawa Y, Merlo A, Frei K, Mariani L, Hofer S. Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib — a phase II trial. Molecular Cancer Therapeutics. 2011;10(6):1102-1112. https://doi.org/10.1158/1535-7163.MCT-11-0048
Uhm JH, Ballman KV, Wu W, Giannini C, Krauss JC, Buckner JC, James CD, Scheithauer BW, Behrens RJ, Flynn PJ, Schaefer PL, Dakhill SR, Jaeckle KA. Phase II evaluation of gefitinib in patients with newly diagnosed grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074. International Journal of Radiation Oncology, Biology, Physics. 2011;80(2):347-353. https://doi.org/10.1016/j.ijrobp.2010.01.070
van den Bent MJ, Brandes AA, Rampling R, Kouwenhoven MC, Kros JM, Carpentier AF, Clement PM, Frenay M, Campone M, Baurain JF, Armand JP, Taphoorn MJ, Tosoni A, Kletzl H, Klughammer B, Lacombe D, Gorlia T. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. Journal of Clinical Oncology. 2009;27(8):1268-1274. https://doi.org/10.1200/JCO.2008.17.5984
Zussman BM, Engh JA. Outcomes of the ACT III Study: Rindopepimut (CDX-110) Therapy for Glioblastoma. Neurosurgery. 2015;76(6):17. https://doi.org/10.1227/01.neu.0000465855.63458.0c
Tebbutt N, Pedersen MW, Johns TG. Targeting the ERBB family in cancer: couples therapy. Nature Reviews Cancer. 2013;13(9):663-673. https://doi.org/10.1038/nrc3559
Lv S, Teugels E, Sadones J, De Brakeleer S, Duerinck J, Du Four S, Michotte A, De Grève J, Neyns B. Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab. International Journal of Oncology. 2012;41(3):1029-1035. https://doi.org/10.3892/ijo.2012.1539
Neyns B, Sadones J, Joosens E, Bouttens F, Verbeke L, Baurain JF, D’Hondt L, Strauven T, Chaskis C, In’t Veld P, Michotte A, De Greve J. Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. Annals of Oncology. 2009;20(9):1596-1603. https://doi.org/10.1093/annonc/mdp032
Hasselbalch B, Lassen U, Hansen S, Holmberg M, Sørensen M, Kosteljanetz M,Broholm H, Stockhausen MT, Poulsen HS. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro-Oncology. 2010;12(5):508-516. https://doi.org/10.1093/neuonc/nop063
Westphal M, Heese O, Steinbach JP, Schnell O, Schackert G, Mehdorn M, Schulz D, Simon M, Schlegel U, Senft C, Geletneky K, Braun C, Hartung JG, Reuter D, Metz MW, Bach F, Pietsch T. A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma. European Journal of Cancer. 2015;51(4):522-532. https://doi.org/10.1016/j.ejca.2014.12.019
Vu T, Claret FX. Trastuzumab: updated mechanisms of action and resistance in breast cancer. Frontiers in Oncology. 2012;2:62. https://doi.org/10.3389/fonc.2012.00062
Greenall SA, Adams TE, Johns TG. Incomplete target neutralization by the anti-cancer antibody rilotumumab. MAbs: Monoclonal Antibodies. 2016;8(2):246-252. https://doi.org/10.1080/19420862.2015.1122149
van den Bent MJ, French P, Eoli M, Sepúlveda JM, Walenkamp AME, Frenel J-S, Franceschi E, Clement PM, Weller M, de Heer I, Looman J, Dey J, Krause S, Xiong H, Ansell PJ, Nuyens S, Spruyt M, Brilhante J, Gorlia T, Golfinopoulos V. Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux-M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406). Neuro-Oncology. 2018;20(3):241. https://doi.org/10.1093/neuonc/noy139.094
Phillips AC, Boghaert ER, Vaidya KS, Mitten MJ, Norvell S, Falls HD, DeVries PJ, Cheng D, Meulbroek JA, Buchanan FG, McKay LM, Goodwin NC, Reilly EB. ABT-414, an antibody-drug conjugate targeting a tumor-selective EGFR epitope. Molecular Cancer Therapeutics. 2016;15(4):661-669. https://doi.org/10.1158/1535-7163.MCT-15-0901
Reilly EB, Phillips AC, Buchanan FG, Kingsbury G, Zhang Y, Meulbroek JA, Cole TB, DeVries PJ, Falls HD, Beam C, Gu J, Digiammarino EL, Palma JP, Donawho CK, Goodwin NC, Scott AM. Characterization of ABT-806, a humanized tumor-specific anti-EGFR monoclonal antibody. Molecular Cancer Therapeutics. 2015;14(5):1141-1151. https://doi.org/10.1158/1535-7163.MCT-14-0820
Gan HK, Burgess AW, Clayton AH, Scott AM. Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy. Cancer Research. 2012;72(12):2924-2930. https://doi.org/10.1158/0008-5472.CAN-11-3898
Jungbluth AA, Stockert E, Huang HJ, Collins VP, Coplan K, Iversen K, Kolb D, Johns TJ, Scott AM, Gullick WJ, Ritter G, Cohen L, Scanlan MJ, Cavenee WK, Old LJ. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proceedings of the National Academy of Sciences of the United States of America. 2003;100(2):639-644.
Scott AM, Lee FT, Tebbutt N, Herbertson R, Gill SS, Liu Z, Skrinos E, Murone C, Saunder TH, Chappell B, Papenfuss AT, Poon AM, Hopkins W, Smyth FE, MacGregor D, Cher LM, Jungbluth AA, Ritter G, Brechbiel MW, Murphy R, Burgess AW, Hoffman EW, Johns TG, Old LJ. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proceedings of the National Academy of Sciences of the United States of America. 2007;104(10):4071-4076.
Gan HK, Burge ME, Solomon BJ, Holen KD, Zhang Y, Ciprotti M, Merdan T, Munasinghe W, Pedersen M, Hintzman PF, Fox GB, Humerickhouse RA, Scott AM. A phase I and biodistribution study of ABT-806i, an 111indium-labeled conjugate of the tumor-specific anti-EGFR antibody ABT-806. Journal of Clinical Oncology. 2013;31(suppl):2520.
Gan HK, Reardon DA, Lassman AB, Merrell R, van den Bent M, Butowski N, Lwin Z, Wheeler H, Fichtel L, Scott AM, Gomez EJ, Fischer J, Mandich H, Xiong H, Lee HJ, Munasinghe WP, Roberts-Rapp LA, Ansell PJ, Holen KD, Kumthekar P. Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma. Neuro-Oncology. 2018;20(6):838-847. https://doi.org/10.1093/neuonc/nox202
Reardon DA, Lassman AB, van den Bent M, Kumthekar P, Merrell R, Scott AM, Fichtel L, Sulman EP, Gomez E, Fischer J, Lee HJ, Munasinghe W, Xiong H, Mandich H, Roberts-Rapp L, Ansell P, Holen KD, Gan HK. Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma. Neuro-Oncology. 2017;19(7):965-975. https://doi.org/10.1093/neuonc/now257
Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM. Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology working group. Journal of Clinical Oncology. 2010;28(11):1963-1972. https://doi.org/10.1200/JCO.2009.26.3541
Greenall SA, McKenzie M, Seminova E, Dolezal O, Pearce L, Bentley J, Kuchibhotla M, Chen SC, McDonald KL, Kornblum H, Endersby R, Adams TE, Johns TG. Most clinical anti-EGFR antibodies do not neutralize both wtEGFR and EGFRvIII activation in glioma. Neuro-Oncology. 2019;21(8):1016-1027. https://doi.org/10.1093/neuonc/noz073

Закрыть метаданные